



ELEKTA INITIATES REPURCHASE OF OWN SHARES

PRESS RELEASE

Stockholm, July 4, 2007

Elekta has on July 4, 2007, repurchased 154,200 B shares at an average price of SEK 117.37. Elekta's current holding of own shares (treasury stock) amounts to 913,471 B shares. The total number of shares in Elekta as of 31 May, 2007 is 93,794,776.

The repurchases currently being carried out follows the Board's decision on July 2, 2007, to mandate executive management to initiate on appropriate occasions the repurchase of shares amounting up to SEK 100 M, but maximized to 1,000,000 shares.

For information regarding implementation of additional purchases within this mandate, Elekta offers reference continually to <http://omxgroup.com/nordicexchange>.

Purchases will be made on the Nordic Exchange and at a price within the registered price interval at the time of each purchase. Purchases may be made during the period until the next Annual General Meeting. Elekta's Board intends to suggest to the AGM that repurchased shares are cancelled.

For further information, please contact:

Okee Williams
Corporate Communications, Elekta AB
Tel: +46 70 600 53 64 (mobile), e-mail: okee.williams@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife[®] for non-invasive treatment of brain disorders and Elekta Synergy[®] for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.